FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099687525> ?p ?o ?g. }

• W2099687525 endingPage "50" @default.
• W2099687525 startingPage "45" @default.
• W2099687525 abstract "Anthracyclines are the most active cytostatic agents in patients with metastatic breast cancer. Drug resistance and dose intensity are relevant issues in the treatment of cancer.A randomized phase II study in 51 patients with advanced progressive metastatic breast cancer was performed. Twenty-six were treated with epirubicin (EPI) 120 mg/m2 i.v. bolus injection divided over three days combined with a daily dose of 480 mg verapamil (VPL) orally administered one day before and during EPI. Twenty-five patients received the same dose and schedule of EPI without VPL. Evaluation of response was carried out after three 21-day cycles. Study endpoints were objective response rate and overall survival.Among the 24 evaluable patients treated with EPI+VPL 1 CR (4%), 7 PR (29%), 9 NC (38%) and 7 PD (29%) were observed. Two patients were excluded because of toxicity. Among the 24 evaluable patients treated with EPI alone 8 PR (28%), 6 NC (24%) and 10 PD (40%) were observed, and one patient was excluded because of toxicity. Myelotoxicity was the major side effect followed by alopecia, stomatitis/mucositis and nausea. The patient group treated with VPL had lower blood pressure levels during therapy, with complete normalization after discontinuation of VPL. The median overall survival times were similar: 7.4 month in the EPI group and 8.9 month in the EPI+VPL group.In both treatment groups the objective response rate was about 30% and the overall survival rates were also the same. No clinical relevance could be demonstrated for the hypothesized resistance modifying action of VPL. Furthermore, VPL did not increase the toxicity of EPI." @default.
• W2099687525 created "2016-06-24" @default.
• W2099687525 creator A5027561867 @default.
• W2099687525 creator A5027572658 @default.
• W2099687525 creator A5033261010 @default.
• W2099687525 creator A5051990929 @default.
• W2099687525 creator A5052479430 @default.
• W2099687525 creator A5076155394 @default.
• W2099687525 creator A5080472244 @default.
• W2099687525 creator A5083748711 @default.
• W2099687525 date "1993-01-01" @default.
• W2099687525 modified "2023-10-15" @default.
• W2099687525 title "Randomized phase II study of single-agent epirubicin +/— verapamil in patients with advanced metastatic breast cancer" @default.
• W2099687525 cites W1824235478 @default.
• W2099687525 cites W1842248410 @default.
• W2099687525 cites W1860873974 @default.
• W2099687525 cites W1866647776 @default.
• W2099687525 cites W1888375872 @default.
• W2099687525 cites W1900639705 @default.
• W2099687525 cites W1936178215 @default.
• W2099687525 cites W1967221808 @default.
• W2099687525 cites W1968042068 @default.
• W2099687525 cites W1976234273 @default.
• W2099687525 cites W1981113318 @default.
• W2099687525 cites W1989970027 @default.
• W2099687525 cites W2008121806 @default.
• W2099687525 cites W2010852139 @default.
• W2099687525 cites W2012431622 @default.
• W2099687525 cites W2036338253 @default.
• W2099687525 cites W2056277564 @default.
• W2099687525 cites W2093774212 @default.
• W2099687525 cites W2139330198 @default.
• W2099687525 cites W2230845873 @default.
• W2099687525 cites W2265230738 @default.
• W2099687525 cites W2305040502 @default.
• W2099687525 cites W2330814896 @default.
• W2099687525 cites W2397662760 @default.
• W2099687525 cites W2413010379 @default.
• W2099687525 cites W2466305728 @default.
• W2099687525 cites W2473387326 @default.
• W2099687525 cites W2615159535 @default.
• W2099687525 cites W4241240326 @default.
• W2099687525 cites W4293241248 @default.
• W2099687525 doi "https://doi.org/10.1093/oxfordjournals.annonc.a058356" @default.
• W2099687525 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8435362" @default.
• W2099687525 hasPublicationYear "1993" @default.
• W2099687525 type Work @default.
• W2099687525 sameAs 2099687525 @default.
• W2099687525 citedByCount "43" @default.
• W2099687525 countsByYear W20996875252012 @default.
• W2099687525 countsByYear W20996875252014 @default.
• W2099687525 countsByYear W20996875252016 @default.
• W2099687525 countsByYear W20996875252017 @default.
• W2099687525 crossrefType "journal-article" @default.
• W2099687525 hasAuthorship W2099687525A5027561867 @default.
• W2099687525 hasAuthorship W2099687525A5027572658 @default.
• W2099687525 hasAuthorship W2099687525A5033261010 @default.
• W2099687525 hasAuthorship W2099687525A5051990929 @default.
• W2099687525 hasAuthorship W2099687525A5052479430 @default.
• W2099687525 hasAuthorship W2099687525A5076155394 @default.
• W2099687525 hasAuthorship W2099687525A5080472244 @default.
• W2099687525 hasAuthorship W2099687525A5083748711 @default.
• W2099687525 hasBestOaLocation W20996875251 @default.
• W2099687525 hasConcept C121608353 @default.
• W2099687525 hasConcept C126322002 @default.
• W2099687525 hasConcept C141071460 @default.
• W2099687525 hasConcept C2775930923 @default.
• W2099687525 hasConcept C2776694085 @default.
• W2099687525 hasConcept C2778496288 @default.
• W2099687525 hasConcept C2778715236 @default.
• W2099687525 hasConcept C2779051857 @default.
• W2099687525 hasConcept C2780580376 @default.
• W2099687525 hasConcept C2780835546 @default.
• W2099687525 hasConcept C2781413609 @default.
• W2099687525 hasConcept C29730261 @default.
• W2099687525 hasConcept C31760486 @default.
• W2099687525 hasConcept C530470458 @default.
• W2099687525 hasConcept C71924100 @default.
• W2099687525 hasConcept C90924648 @default.
• W2099687525 hasConceptScore W2099687525C121608353 @default.
• W2099687525 hasConceptScore W2099687525C126322002 @default.
• W2099687525 hasConceptScore W2099687525C141071460 @default.
• W2099687525 hasConceptScore W2099687525C2775930923 @default.
• W2099687525 hasConceptScore W2099687525C2776694085 @default.
• W2099687525 hasConceptScore W2099687525C2778496288 @default.
• W2099687525 hasConceptScore W2099687525C2778715236 @default.
• W2099687525 hasConceptScore W2099687525C2779051857 @default.
• W2099687525 hasConceptScore W2099687525C2780580376 @default.
• W2099687525 hasConceptScore W2099687525C2780835546 @default.
• W2099687525 hasConceptScore W2099687525C2781413609 @default.
• W2099687525 hasConceptScore W2099687525C29730261 @default.
• W2099687525 hasConceptScore W2099687525C31760486 @default.
• W2099687525 hasConceptScore W2099687525C530470458 @default.
• W2099687525 hasConceptScore W2099687525C71924100 @default.
• W2099687525 hasConceptScore W2099687525C90924648 @default.
• W2099687525 hasIssue "1" @default.
• W2099687525 hasLocation W20996875251 @default.
• W2099687525 hasLocation W20996875252 @default.

• next